ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2022, Vol. 36 ›› Issue (2): 68-71.doi: 10.6040/j.issn.1673-3770.0.2021.059
Previous Articles Next Articles
ZHANG Taoran, WANG Wei, LI Mingming, HUANG Yingxiang
CLC Number:
| [1] Xie SQ, Fang YX, Du R, et al. Role of dilated subfoveal choroidal veins in eyes with myopic macular neovascularization[J]. Retina, 2021, 41(5): 1063-1070. doi:10.1097/IAE.0000000000002970. [2] Coco-Martin RM, Belani-Raju M, de la Fuente-Gomez D, et al. Progression of myopic maculopathy in a Caucasian cohort of highly myopic patients with long follow-up: a multistate analysis[J]. GraefesArch Clin Exp Ophthalmol, 2021, 259(1): 81-92. doi:10.1007/s00417-020-04795-5. [3] Ohno-Matsui K, Ikuno Y, Lai TYY, et al. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia[J]. Prog Retin Eye Res, 2018, 63: 92-106.doi:10.1016/j.preteyeres.2017.10.005. [4] Kasahara K, Moriyama M, Morohoshi K, et al. Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia[J]. Retina, 2017, 37(6): 1055-1064.doi:10.1097/IAE.0000000000001313. [5] Toto L, di Antonio L, Costantino O, et al. Anti-VEGF therapy in myopic CNV[J]. Curr Drug Targets, 2021, 22(9): 1054-1063. doi:10.2174/1389450122999210128180725. [6] Karagiannis D, Kontadakis G, Kaprinis K, et al. Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age[J]. Clin Ophthalmol, 2017, 11: 1197-1201. doi:10.2147/opth.s135174. [7] Wang HY, Tao MZ, Wang XX, et al. Baseline characteristics of myopic choroidal neovascularization in patients above 50 years old and prognostic factors after intravitreal conbercept treatment[J]. SciRep, 2021, 11(1): 7337. doi:10.1038/s41598-021-86835-6. [8] Cohen SY, Tabary S, El Ameen A, et al. Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab[J]. Albrecht Von Graefes Arch Fur Klinische Und ExpOphthalmol, 2019, 257(3): 485-493. doi:10.1007/s00417-018-04205-x. [9] Borrelli E, Battista M, Vella G, et al. Three-year OCT predictive factors of disease recurrence in eyes with successfully treated myopic choroidal neovascularisation[J]. Br J Ophthalmol, 2021: bjophthalmol-bjophtha2020-318440. doi:10.1136/bjophthalmol-2020-318440. [10] Coelho J, Ferreira A, Abreu AC, et al. Choroidal neovascularization secondary to pathological myopia—macular Bruch membrane defects as prognostic factor to anti-VEGF treatment[J]. Graefes ArchClin Exp Ophthalmol, 2021. doi:10.1007/s00417-021-05142-y. [11] Ahn SJ, Park KH, Woo SJ. Subfoveal choroidal thickness changes following anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization[J]. Invest Ophthalmol Vis Sci, 2015,56(10): 5794-5800. doi:10.1167/iovs.14-16006. [12] Xie JM, Chen QY, Yu JY, et al. Morphologic features of myopic choroidal neovascularization in pathologic myopia on swept-source optical coherence tomography[J]. Front Med(Lausanne), 2020, 7: 615902. doi:10.3389/fmed.2020.615902. [13] Melzer C, Ziemssen F, Eter N,. Design and baseline characteristics of the help study: an extended and long-term observation of pathological myopia in caucasians[J]. Ophthalmologica, 2018, 240(3): 167-178. doi: 10.1159/000489180. [14] Wang Y, Hu ZL, Zhu TP, et al. Optical coherence tomography angiography-based quantitative assessment of morphologic changes in active myopic choroidal neovascularization during anti-vascularendothelial growth factor therapy[J]. Front Med(Lausanne), 2021, 8: 657772. doi:10.3389/fmed.2021.657772. [15] Ahn SJ, Woo SJ, Kim KE, et al. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization[J]. Invest Ophthalmol Vis Sci, 2013, 54(3): 2115-2122. doi: 10.1167/iovs.12-11542. [16] Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study[J]. Ophthalmology, 2015, 122(6): 1220-1227.doi:10.1016/j.ophtha.2015.01.025. [17] 刘志高, 王淑雅, 韩旭光, 等. 增殖性糖尿病视网膜病变术前玻璃体腔应用阿柏西普的时机及其疗效观察[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 99-103. doi:10.6040/j.issn.1673-3770.0.2020.250. LIU Zhigao, WANG Shuya, HAN Xuguang, et al. Preoperative timing and the effect of intravitreal aflibercept injection for proliferative diabetic retinopathy patients[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(1): 99-103. doi:10.6040/j.issn.1673-3770.0.2020.250. [18] Tan NW, Ohno-Matsui K, Koh HJ, et al. Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in east-Asian patients from the radiance study[J]. Retina, 2018, 38(11): 2228-2238. doi:10.1097/iae.0000000000001858. [19] Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study[J]. Ophthalmology, 2013, 120(9): 1944-5.e1.doi:10.1016/j.ophtha.2013.06.010. [20] Gabrielle PH, Nguyen V, Creuzot-Garcher C, et al. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness Registry[J]. Acta Ophthalmol, 2021. doi:10.1111/aos.14893. [21] Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia[J]. Ophthalmology, 2014, 121(3): 682-692.e2. doi:10.1016/j.ophtha.2013.10.023. [22] Chen YX, Sharma T, Li XR, et al. Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization[J]. Retina, 2019, 39(10): 1985-1994. doi:10.1097/iae.0000000000002292. [23] Xiao H, Zhao XJ, Li SS, et al. Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation[J]. Br J Ophthalmol, 2021, 105(1): 103-108. doi:10.1136/bjophthalmol-2019-315763. |
| [1] | ObjectiveObjectiveTo analyze the literature on ocular ischemic syndrome published between January , and December , . MethodPapers on OIS that were published between January , and December , , were screened and retrieved from the CNKI and WOS databases, and those that were relevant were searched and analyzed. ResultsIn this analysis, Chinese papers on OIS were cited for times with an h-index of , while foreign papers were cited for times with an h-index of . Of the organizations that published the highest number of papers and had the highest h-indexes, the Capital Medical University and the Polish Medical University of Pomerania were the leading institutions. The Chinese Journal of Ophthalmology was the leading domestic journal, and the Journal of Ophthalmology and Plos One were the leading foreign journals. China published the highest number of papers abroad, China and South Korea had the highest h-indexes. China′s National Natural Science Foundation provided the most support to the field of OIS, accounting for .% of the total domestic literature. The most frequently cited article in the WOS database was by Hayreh, SS, which was on the prevalence and pathogenesis of ocular vascular occlusive disease and melanosis, it was also part of the top ten studies that focused on the utility of OCT in providing insights into OIS and the mechanisms of ischemia and hypoxia. ConclusionThe utility of OCT in providing insights into OIS and the mechanisms of hypoxia and ischemia represents a modern focus of researchers.. Analysis of the literature on ocular ischemic syndrome at home and abroadMENG Bo, HUANG Yingxiang, WANG Kang, ZHAO Lu, WANG Yanling Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 35-40. |
| [2] | To describe characteristics and risk factors associated with central serous chorioretinopathy(CSC)in a hospital-based outpatient sample population. MethodsIn this hospital-based cross-sectional study, CSC patients were recruited from the Beijing Friendship Hospital from 01/2019 to 12/2019. All participants underwent a standardized interview. Logistic regression models were used to assess the risk factors associated with CSC. ResultsA total of 23,878 outpatients were recorded during the period 01/2019-12/2019. Of these, 45 patients(0.19%)were diagnosed with CSC, divided in 37 male patients(82.22%)and 8 female patients(17.78%). The patients′ age ranged from 21 to 65(42.3±10.1)years. Three patients(6.67%)presented a bilateral involvement. Of all the patients, 39 were included in the present analysis. Control patients were matched for age and sex at a ratio of 1:1. The presence of CSC was associated with exposure to steroids(OR=5.04, 95% CI:1.11-22.89), sleep time(going to sleep after 12 pm)(OR=4.16, 95% CI:1.33-13.04)),and shift-work(OR=5.74, 95% CI:1.47-22.45).ConclusionsOur data showed that CSC prevalence in the analyzed outpatients was 0.19%. Exposure to steroids, sleep time, and shift-work were factors related with CSC in the observed population.. Prevalence and risk factors of central serous chorioretinopathy in a hospital-based population YANG Xiufen, YOU Ran, MA Xiumei, WANG Kang, WANG Yanling Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, ChinaAbstract:Objective〓 [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 75-79. |
| [3] | YANG Xiufen, LI Hongyang, ZHAO Lu,WEI Ying, HU Xiangdong, CHEN Jun, WANG Yanling. Clinical and imaging characteristics in patients with ocular ischemic syndrome [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 119-123. |
| [4] | . Causes of non-traumatic vitreous hemorrhage and effects of surgical treatment. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(1): 107-109. |
| [5] | . Clinical observation on the treatment of BRVO-ME by the combination of laser therapy with Ranibizumab intravitreal injection. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(1): 110-113. |
| [6] | ZHAO Lu, XIE Guoli, WANG Yanling. Changes of ocular hemodynamics after intravitreal ranibizumab injection in patients with wet age-related macular degeneration. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 101-104. |
| [7] | YAN Xiaoteng, FENG Jun, KANG Xinle. Intravitreal injection of conbercept for macular edema secondary to retinal vein occlusion. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 105-108. |
| [8] | YAN Xiao-teng, FENG Jun, KANG Xin-le. Intravitreal triamcinolone acetonide combined with grid laser photocoagulation for patients with cystoid macular edema [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(1): 60-63. |
| [9] | LI Hao, ZHOU Fang. Idiopathic macular hole surgery prognosis based on macular hole size [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(2): 81-83. |
| [10] | LIU Min1, GUO Jian-lian1， ZHANG Hua2. Vitrectomy in treating idiopathic macular epiretinal membrane [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(5): 65-67. |
| [11] | SHAO Yan1, XU Xin-rong2. Advances in study of traditional Chinese medicine on age-related macular degeneration [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(5): 91-94. |
| [12] | FAN Xu, GUAN Juan, ZHAO Hui-ying, WANG Qian, SHENG Yu. One case of congenital macular coloboma [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2012, 26(3): 93-94. |
| [13] | . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2011, 25(6): 80-82. |
| [14] | CAI Ke-bo. Internal limiting membrane peeling for treatment of foveoschisis in high myopia [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2011, 25(5): 108-110. |
| [15] | . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2009, 23(5): 71-72. |
|